Noah Agada

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

Andrew Blauvelt, Melinda Gooderham, Lars Iversen et al. · Journal of the American Academy of Dermatology · 2017 · 111 citations · Full text

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

April W. Armstrong, C. Paul, L. Puig et al. · Dermatology and Therapy · 2019 · 67 citations · Full text

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

Richard G. Langley, Alexa B. Kimball, Himmet Nak et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 60 citations

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

Richard G. Langley, Kim Papp, Melinda Gooderham et al. · British Journal of Dermatology · 2018 · 58 citations · Full text

Obesity's effect on asthma extends to diagnostic criteria

Njira Lugogo, Cynthia L. Green, Noah Agada et al. · Journal of Allergy and Clinical Immunology · 2017 · 56 citations · Full text

Asthma, Metabolic Syndrome, Obesity +4